Advanced prompting as a catalyst: Empowering large language models in the management of gastrointestinal cancers

Abstract

<p>Large Language Models' (LLMs) performance in healthcare can be significantly impacted by prompt engineering. However, the area of study remains relatively uncharted in gastrointestinal oncology until now. Our research delves into this unexplored territory, investigating the efficacy of varied prompting strategies, including simple prompts, templated prompts, in-context learning (ICL), and multi-round iterative questioning, for optimizing the performance of LLMs within a medical setting. We develop a comprehensive evaluation system to assess the performance of LLMs across multiple dimensions. This robust evaluation system ensures a thorough assessment of the LLMs' capabilities in the field of medicine. Our findings suggest a positive relationship between the comprehensiveness of the prompts and the LLMs' performance. Notably, the multi-round strategy, which is characterized by iterative question-and-answer rounds, consistently yields the best results. ICL, a strategy that capitalizes on interrelated contextual learning, also displays significant promise, surpassing the outcomes achieved with simpler prompts. The research underscores the potential of advanced prompt engineering and iterative learning approaches for boosting the applicability of LLMs in healthcare. We recommend that additional research be conducted to refine these strategies and investigate their potential integration, to truly harness the full potential of LLMs in medical applications.</p>

Helicobacter pylori and immunotherapy for gastrointestinal cancer

“… 18 , 19 , 20 , 21 The efficacy of immunotherapy may differ in different types of cancer, emphasizing the importance of personalized approaches guided by robust clinical evidence. 22 To overcome tumor heterogeneity and identify patients who could benefit from anti-PD-1/PD-L1 therapy, several biomarkers, including PD-L1 combined positive score (CPS), Epstein-Barr virus (EBV) infection, dMMR or MSI-H status, and other biomarkers, have been developed for stratifying GI cancers. 19 , 23 , 24 , 25 , 26 Our previous research emphasized the significant association between tumor microenvironment (TME) and clinical efficacy of immunotherapy in patients with GC.…”